MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...
Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...
The Senate officially confirmed Robert F. Kennedy Jr.'s nomination as secretary of Health and Human Services on Thursday. The final vote count was 52 in favor and 48 against, with Sen. Mitch McConnell ...
Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
The Moderna and Pfizer agreements include options for a total of 600 million doses, 300 million apiece, but these can only be exercised with additional funding from Congress, according to HHS.
Antibiotics marked the transition to the modern Pfizer. Their follow-up to penicillin, Terramycin, first marketed in 1950, was both their first proprietary drug, and the first for which the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback